Scribe Therapeutics Presents Updated Cardiovascular Therapy Data at AHA Scientific Sessions

• Scribe Therapeutics will attend the American Heart Association Scientific Sessions in Chicago on Nov. 6-9, 2026.
• A Nov. 7 late-breaking presentation will cover STX-1150’s LDL cholesterol control lasting at least two years following one dose in nonhuman primates.
• A second Nov. 7 presentation will focus on STX-1200’s durable reduction of lipoprotein(a) across preclinical models.
• CEO Benjamin Oakes will participate in AHA Innovation Forum sessions on entrepreneurship and artificial intelligence in cardiovascular innovation on Nov. 6.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scribe Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040800PRIMZONEFULLFEED9869961) on November 04, 2026, and is solely responsible for the information contained therein.